Rabies Immune Globulin
drugOn this page
Also known as Human rabies globulin (hrig)HyperrabImogamKamrabRabies immune globulin (human)Rabies immune globulin humanhumanRabies immunoglobulinRabies immunoglobulins
Summary
Rabies Immune Globulin (CHEMBL1201600) is a phase-3 clinical-stage unknown (ATC J06BB05); indicated across 2 conditions including rhabdoviridae infectious disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- ATC class: J06BB05
- Indications: 2 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201600 |
| Name | Rabies Immune Globulin |
| Type | Unknown |
| Max phase | 3 |
| ATC | J06BB05 |
Also known as: Human rabies globulin (hrig), Hyperrab, Imogam, Kamrab, Rabies immune globulin, Rabies immune globulin (human), Rabies immune globulin human, human, Rabies immunoglobulin, Rabies immunoglobulins, RABIES IMMUNE GLOBULIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| Rhabdoviridae infectious disease | 3 | MONDO:0005944 | EFO:0007469 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02177032 | PHASE3 | COMPLETED | Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age |
| NCT03264157 | PHASE2/PHASE3 | COMPLETED | Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects |
| NCT03965962 | PHASE3 | COMPLETED | Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults |
| NCT07399951 | EARLY_PHASE1 | COMPLETED | Washington University WU 409: Immune Responses to Rabies Vaccine. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: Rhabdoviridae infectious disease